NuVasive to Present at the 8th Annual Needham Life Sciences Conference

jiqatili.wordpress.com
A live webcast of the presentation will be available online from the investof relations page ofthe Company's corporatew website at . After the live webcast, the presentation will remai available on the website for 30 NuVasive is a medical device company focusede onthe design, development, and marketingt of products for the surgical treatmeny of spine disorders. The Company's product portfolio is focusef primarily onthe $4.6 billion U.S. spine implant Additionally, the Company has expanded intothe $1.5 billionj global biologics market, the $1.5 billion international and is developing products for the emerging motio n preservation market.
NuVasive's principal product offering is based on its Maximum Access or MAS(R) platform. The MAS platform combines four categories of products that collectivelgy minimize soft tissue disruption duriny spine surgery with maximum visualization and easy reproducibility forthe surgeon: a proprietary software-driven nerve avoidance system; MaXcess(R), a uniqu e split-blade retractor system; a wide variett of specialized implants; and several biologixc fusion enhancers. MAS significantly reduces surgery time and returnds patients to activities of daily living much fastedr thanconventional approaches.
Having redefined spined surgery with theMAS platform'sx lateral approach, known as eXtreme Latera Interbody Fusion, or XLIF(R), NuVasive has builrt an entire spine franchise. With nearlt 50 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offeriny predicated onits R&eD focus and dedication to outstandinf service levels supported by a culture of Absolutd Responsiveness(R).
NuVasive cautions you that statements included in this press releasd that are not a descriptiojn of historical factsare forward-looking statements that involve risks, assumptions and other factors which, if they do not materializre or prove correct, could causre NuVasive's results to diffedr materially from historical results or those expressedx or implied by such forward-looking The potential risks and uncertainties that could cause actualk growth and results to differ materially but are not limited to: the uncertain processx of seeking regulatory approval or clearancde for NuVasive's products or including risks that such procesds could be significantly delayed; the possibilith that the FDA may require significanyt changes to NuVasive's products or clinical studies; the risk that productw may not perform as intended and may thereforre not achieve commercial success; the risk that competitora may develop superior products or may have a greater markef position enabling mo re successful commercialization; the risk that additional clinicall data may call into question the benefitss of NuVasive's products to patients, hospitals and and other risks and uncertainties more fully described in NuVasive'd press releases and periodic filingws with the Securities and Exchang Commission.
NuVasive's public filings with the Securities and Exchange Commissionn are availableat . NuVasive assumes no obligationm to updateany forward-looking statement to reflectg events or circumstances arising after the date on whichj it was made. Contact: Investors: Kevin C. O'Boyle Patrick F. Williams EVP Chief Financial OfficerVice President, Finance Investor Relations NuVasive, Inc. NuVasive, Inc. 858-909-1999 858-638-5511 investorrelations@nuvasive.com investorrelations@nuvasive.com Media: Jason Rando The Ruth Groulp 646-536-7025 jrando@theruthgroup.com SOURCE NuVasive, Inc.